This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Seattle Genetics To Present Clinical Data From Broad ADCETRIS® (Brentuximab Vedotin) Development Program And Novel Antibody-Drug Conjugate (ADC) SGN-CD19A At ASH 2013

Stocks in this article: SGEN

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that multiple abstracts will be presented at the 55 th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in New Orleans, Louisiana, December 7-10, 2013, highlighting the following:

  • Clinical data for ADCETRIS (brentuximab vedotin) in CD30-positive lymphomas, including Hodgkin lymphoma (HL), mature T-cell lymphoma (MTCL), cutaneous T-cell lymphoma (CTCL) and diffuse B-cell lymphoma (DLBCL);
  • Interim phase 1 clinical data for SGN-CD19A, a novel antibody-drug conjugate (ADC), in acute lymphoblastic leukemia (ALL); and
  • Final phase 1 data from two ADC candidates that utilize Seattle Genetics’ proprietary technology being developed by Genentech, a member of the Roche Group (SIC: RO, ROG; OTCQX: RHHBY), including an anti-CD22 ADC (pinatuzumab vedotin, RG7593) and an anti-CD79b ADC (polatuzumab vedotin, RG7596).

“The presentations at ASH demonstrate the breadth of our development program for ADCETRIS in CD30-positive malignancies, including frontline and relapsed patients and disease areas ranging from Hodgkin lymphoma to mature T-cell lymphoma and diffuse large B-cell lymphoma,” said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics. “Beyond ADCETRIS, we continue to make progress in advancing our robust ADC pipeline, including SGN-CD19A, which is currently being evaluated in ALL and aggressive non-Hodgkin lymphoma. Finally, our collaborators continue to advance potential therapeutic options for patients and are making progress with ADCs utilizing our technology.”

ADCETRIS is an ADC directed to CD30, which is known to be expressed in HL and systemic anaplastic large cell lymphoma (sALCL), as well as in many types of CTCL, B-cell lymphomas and MTCL. Across corporate and investigator-sponsored trials, ADCETRIS is being evaluated in more than 20 ongoing clinical trials, including four phase 3 studies. ADCETRIS is currently not approved for use in CTCL, B-cell non-Hodgkin lymphoma, salvage HL or frontline treatment of MTCL and HL.

1 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs